150 related articles for article (PubMed ID: 37077065)
1. Role of CD44 as cancer stem cell marker in triple-negative breast cancer and its association with histological grade and angiogenesis.
Tomar R; Rakheja G; Verma N; Thakur S; Khurana N; Ghuliani D
Indian J Pathol Microbiol; 2023; 66(2):258-263. PubMed ID: 37077065
[TBL] [Abstract][Full Text] [Related]
2. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
6. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
7. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas.
Oliveira-Costa JP; Zanetti JS; Silveira GG; Soave DF; Oliveira LR; Zorgetto VA; Soares FA; Zucoloto S; Ribeiro-Silva A
Diagn Pathol; 2011 Aug; 6():73. PubMed ID: 21824412
[TBL] [Abstract][Full Text] [Related]
9. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
10. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
11. Association of human breast cancer CD44
Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
Elife; 2021 Jul; 10():. PubMed ID: 34318746
[TBL] [Abstract][Full Text] [Related]
12. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
16. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
17. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
18. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
19. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
[TBL] [Abstract][Full Text] [Related]
20. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
